Physician profile
John E Ammon
NPI 1215973524
$7,526.49
in general payments reported to CMS, 2019-2025
39 companies · $898 in 2025
The $898 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,736 · 2020: $1,125 · 2021: $574 · 2022: $898 · 2023: $1,284 · 2024: $1,012 · 2025: $898.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,193.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,737.70 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,050.73 | 2019-2025 | |
| Lilly USA, LLC | $1,029.80 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $458.60 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $417.62 | 2019-2025 | Farxiga, Airsupra |
| Abbott Laboratories | $354.33 | 2019-2025 | Freestyle Libre 3, Freestyle Libre |
| Abbvie INC. | $353.76 | 2021-2025 | Qulipta, Ubrelvy |
| Amgen INC. | $300.78 | 2019-2025 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $284.14 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $160.67 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $148.01 | 2019-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $130.13 | 2019-2024 | Trulance, Xifaxan |
| Radius Health, INC. | $97.00 | 2019 | |
| Amarin Pharma, INC. | $89.74 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $83.54 | 2019-2023 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $74.17 | 2021-2025 | Gvoke Hypopen |
| Astellas Pharma US INC | $59.56 | 2019-2025 | Veozah |
| Allergan, INC. | $57.30 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $54.42 | 2021-2025 | Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $53.74 | 2019-2024 | Eliquis |
| Sanofi-Aventis U.S. LLC | $49.27 | 2019-2022 | |
| Exact Sciences Corporation | $49.06 | 2025 | Cologuard Collection Kit |
| Eisai INC. | $47.59 | 2024 | |
| Daiichi Sankyo INC. | $43.29 | 2019-2020 | |
| Dexcom, INC. | $38.62 | 2024 | Dexcom G6 Transmitter |
| Ibsa Pharma INC. | $35.22 | 2019-2023 | Tirosint, Licart |
| Horizon Therapeutics Plc | $31.61 | 2019-2023 | Krystexxa |
| Endogastric Solutions, INC | $30.00 | 2024 | Esophyx |
| Sumitomo Pharma America, INC. | $28.33 | 2023 | Gemtesa |
| Vivus LLC | $25.94 | 2019 | |
| Melinta Therapeutics, LLC | $22.83 | 2025 | Orbactiv, Kimyrsa, Rezzayo |
| Biogen, INC. | $21.87 | 2024 | Leqembi |
| Takeda Pharmaceuticals U.S.A., INC. | $21.38 | 2019 | |
| Dynavax Technologies Corporation | $17.52 | 2023 | Heplisav-B |
| Pulmonx Corporation | $16.26 | 2023 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Pharmacosmos Therapeutics INC. | $14.85 | 2025 | Monoferric |
| Lifescan, INC. | $14.67 | 2019 | |
| Medtronic Minimed, INC. | $11.51 | 2020 | |
| Gilead Sciences, INC. | $10.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ammon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.